innovation

Poster – (ECM 2022) Development of innovative hiPSC-based model including an innovative 3D modified hyaluronic acid hydroscaffold for phenotypic screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…

By Grégory MAUBON, ago

HCS Pharma is selected for the co-innovation program France-Singapore 2022 of BPI France and Hello Tomorrow

We are very please to annonce our selection in the “CO-INNO INTERNATIONAL” program. Jointly organised by BPI France and Hello Tomorrow, the CO-INNO program accelerates and supports the most cutting-edge French startups from the discovery of the Singaporean ecosystem to the establishment of technological partnerships, funding and even their settlement Read more…

By Grégory MAUBON, ago

HCS Pharma awarded by an Innovation Award from NHRI during BioAsia in Taïwan

During the last BIO Asia-Taiwan event HCS Pharma was awarded by the National Health Research Institute (NHRI) as a key company (關鍵新創) in the “Partnering and Medical Innovation” category (攜手同行暨創醫獎) for the BIOMIMESYS® technology. BIOMIMESYS® was recognized as a groundbreaking technology, allowing to reproduce any type of healthy or cancerous Read more…

By Grégory MAUBON, ago